NTRB 最新10-Q变化

相对上期新增的文字 · 来源:10-Q · 2026-06-11

• For the three months ending April 30, 2026, we used cash of $563,104 in our operations. The principal adjustments to our net loss of $1,241,956 were depreciation and amortization of $34,177, and the issuance of warrants for services in the amount of $552,458.

• For the three months ending April 30, 2026, no cash was provided from financing activities .

相对上期删除的文字 · 来源:10-Q · 2025-12-11

• For the nine months ending October 31, 2025, we generated revenue of $1,635,942 and our revenue costs were $1,158,575, resulting in a gross profit of $477,367. For the nine months ending October 31, 2024, we generated revenue of $1,497,158 and our costs of revenue were $1,039,785, resulting in a gro…

• For the nine months ending October 31, 2025, our selling, general and administrative expenses were $6,071,320, primarily legal, accounting and compensation expenses compared to $2,554,155 for the nine months ending October 31, 2024. The increase from 2024 is primarily attributable to increases in eq…

• During the nine months ending October 31, 2025, the Company incurred research and development expenses of its Aversa Fentanyl product of $1,703,093, primarily of salaries and increases in development costs from Kindeva as compared to $2,629,278 for the nine months ending October 31, 2024. The decrea…

• We incurred interest expenses of $17,201 for the nine months ending October 31, 2025, as compared to $17,668 for the nine months ending October 31, 2024.

• Interest income for the nine months ending October 31, 2025 was $52,674 as compared to $145,585 for the nine months ending October 31, 2024. The decrease is primarily due to cash used in the Company development operations.

相对上期新增的文字 · 来源:10-Q · 2026-06-11

• Operating lease liability-net of current portion 40,350 48,305

• Net loss per share attributable to common stockholders - basic and diluted $(0.10) $(0.12)

• Weighted average common shares outstanding - basic and diluted 12,155,983 11,125,800

• Proceeds from sale of common stock and exercise of warrants - -

• as of and for the Three Months Ended April 30, 2026 and 2025

相对上期删除的文字 · 来源:10-Q · 2025-12-11

• Employee stock options exercised for settlement of debt 317,110 120,000 120 -

• Number of Number of Paid In Comprehensive Accumulated Treasury

• Total shares Amount shares Amount Capital Income(Loss) Deficit Stock

• Common stock and warrants issued for conversion of debt 672,958 76,230 76 -

• Number of Number of Paid In Comprehensive Accumulated Treasury

相对上期新增的文字 · 来源:10-Q · 2026-06-11

• The United States at the time of this filing is involved with a war with Iran, the outcome of which could result in changes adverse to us in domestic and international markets, including on tariffs and health care and medical products. These changes could affect our promotional activities and our pr…

• There is further economic uncertainty concerning economic policies being pursued by the current administration in the United States that may affect the costs and timing of the process of bringing our products to market through approvals with the FDA.

相对上期删除的文字 · 来源:10-Q · 2025-12-11

• There is economic uncertainty concerning economic policies being pursued by the current administration in the United States that may affect the costs and timing of the process of bringing our products to market through approvals with the FDA.